Fresenius Kabi acquire mAbxience and Ivenix

INICIO/Noticias Farmacéuticas | Posted 15/04/2022 post-comment0 Post your comment

Fresenius Kabi is acquiring a majority stake in biosimilars company mAbxience, and is acquiring infusion pump maker, Ivenix outright. The deals are set to be completed by mid-2022.

Application V15a16

German injectable medicines specialist, Fresenius Kabi is acquiring 55% in mAbxience – a subsidiary of Spanish drugmaker Insud Pharma. Fresenius Kabi is paying €495 million (around US$550 million) upfront as well as undisclosed milestone payments. It has also been announced that there will be the option to buy remaining shares.

This acquisition will enhance Fresenius Kabi’s biosimilars capabilities, giving them two commercially available biosimilars (rituximab and bevacizumab) and a pipeline of several others in development. These are added to the company’s existing adalimumab and pegfilgrastim that have been developed and approved in some regions [1-5], and tocilizumab and others in various stages of development. The deal also comes with three biomanufacturing facilities, two in Spain and one in Argentina and a contract development and manufacturing (CDMO) network.

Fresenius Kabi is also acquiring US infusion therapy company Ivenix for US$240 million, split between upfront and milestone payments. They will then own Ivenix’s FDA approved smart infusion system which has an innovative smartphone-like digital interface designed to reduce infusion-related errors and drive down costs. This can be conveniently paired with Fresenius Kabi’s range of intravenous fluids and infusion devices.

These acquisitions have been made to support the company’s ‘Vision 2026’ plan for expanding its medtech and biopharmaceutical capabilities.

Related articles
Fresenius Kabi signs marketing agreement for adalimumab biosimilar

Generics applications under review by EMA – January 2020

EMA approval for adalimumab biosimilars Idacio and Kromeya


The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View last week’s headline article: Biocomparables aprobados en México

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.


Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de la semana pasada: Biocomparables aprobados en México

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 


1. GaBI Online - Generics and Biosimilars Initiative. EMA recommends approval of teriparatide and pegfilgrastim biosimilars []. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Apr 15]. Available from:
2. GaBI Online - Generics and Biosimilars Initiative. Canada approves five adalimumab biosimilars in last six months []. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Apr 15]. Available from:
3. GaBI Online - Generics and Biosimilars Initiative. Latest launches for adalimumab biosimilarsin Canada and Japan []. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Apr 15]. Available from:
4. GaBI Online - Generics and Biosimilars Initiative. Fresenius Kabi’s pegfilgrastim biosimilar accepted for review by EMA and FDA []. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Apr 15]. Available from:
5. GaBI Online - Generics and Biosimilars Initiative. Adalimumab biosimilar Idacio launched in Germany []. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Apr 15]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2022 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
El recorrido del biológico de continuación Pectuna (pertuzumab) en Irán
Cancer Cell V13I20
INICIO/Noticias Farmacéuticas Posted 29/02/2024
Fiocruz y Pfizer firman un acuerdo para el genérico de Xeljanz
Remicade V13F28
INICIO/Noticias Farmacéuticas Posted 30/01/2024
Genfar: La nueva marca de genéricos de Eurofarma en América Latina
10 AA008993
INICIO/Noticias Farmacéuticas Posted 12/12/2023
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010